Patents by Inventor Marc Nasoff

Marc Nasoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200040054
    Abstract: Provided herein are ERFE fusion polypeptides, compositions and methods of use for treatment, for example in treatment of iron metabolism disorders.
    Type: Application
    Filed: October 2, 2017
    Publication date: February 6, 2020
    Inventors: Xin DU, Vanessa CICCHINI, Justin CHAPMAN, Hua WU, Marc NASOFF
  • Publication number: 20190300620
    Abstract: Engineered effector cells, such as chimeric antigen receptors (CARs), are used for enhanced immunogenic response to specific antigen, such as CD46. Disclosed herein are compositions and methods of treatment a cancer overexpressing CD46, which comprises a pharmaceutical composition comprising an engineered effector cell.
    Type: Application
    Filed: November 10, 2017
    Publication date: October 3, 2019
    Inventors: Marc NASOFF, Joshua PARK
  • Publication number: 20190284274
    Abstract: Provided herein are ERFE specific antibodies, compositions and methods of use for detection of ERFE polypeptides.
    Type: Application
    Filed: August 4, 2017
    Publication date: September 19, 2019
    Inventors: Xin DU, Justin CHAPMAN, Marc NASOFF, Tina Michele SACH, Vanessa CICCHINI, Hua WU
  • Publication number: 20170355775
    Abstract: This disclosure relates to immunogens and monoclonal antibodies useful in the identification and/or treatment of cancer cells, including those of the dog. In one example, chimeric anti-canine CD20 antibodies are provided. The antibodies can be used therapeutically to treat lymphoma in dogs.
    Type: Application
    Filed: August 24, 2017
    Publication date: December 14, 2017
    Inventors: Sarah Rue, Brendan Eckelman, Quinn L. Deveraux, Marc Nasoff
  • Patent number: 9790280
    Abstract: This disclosure relates to immunogens and monoclonal antibodies useful in the identification and/or treatment of cancer cells, including those of the dog. In one example, chimeric anti-canine CD20 antibodies are provided. The antibodies can be used therapeutically to treat lymphoma in dogs.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: October 17, 2017
    Assignee: Elanco Tiergesundheit AG
    Inventors: Sarah Rue, Brendan Eckelman, Quinn Deveraux, Marc Nasoff
  • Patent number: 8173128
    Abstract: Anti-DR5 antibody agonists, combined with apoptosis-inducing agents, synergistically induce apoptosis in cancer cells.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: May 8, 2012
    Assignee: IRM LLC
    Inventors: Marc Nasoff, Quinn L. Deveraux, Deborah A. Knee, Pedro Aza-Blanc, Garrett M. Hampton, Klaus Wagner
  • Publication number: 20120027756
    Abstract: Disclosed in the present invention are antibodies that specifically recognize and antagonize human TSLP receptor, and methods of employing these antibodies to treat or ameliorate diseases or disorder mediated by TSLP signaling.
    Type: Application
    Filed: September 23, 2011
    Publication date: February 2, 2012
    Applicant: IRM LLC
    Inventors: Liqun DONG, Marc NASOFF
  • Patent number: 8101182
    Abstract: Disclosed in the present invention are antibodies that specifically recognize and antagonize human TSLP receptor, and methods of employing these antibodies to treat or ameliorate diseases or disorder mediated by TSLP signaling.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: January 24, 2012
    Assignee: Novartis AG
    Inventors: Liqun Dong, Marc Nasoff
  • Patent number: 8097705
    Abstract: Disclosed in the present invention are antibodies that specifically recognize and antagonize human TSLP receptor, and methods of employing these antibodies to treat or ameliorate diseases or disorder mediated by TSLP signaling.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: January 17, 2012
    Assignee: IRM LLC
    Inventors: Liqun Dong, Marc Nasoff
  • Patent number: 8012703
    Abstract: Methods of using microarrays to simplify analysis and characterization of genes and their function are provided. Such methods can be used to identify and characterize antibodies having binding affinity for a specific target antigen. A method of determining gene expression at the protein level by contacting an array of characterized or uncharacterized antibodies on a solid surface with one or more proteins and identifying the antibodies to which said protein(s) binds also is provided. This method can be used to compare the protein expression in two different populations of cells, such as normal cells and cancer cells or resting cells and stimulated cells. In addition, a method of determining gene expression at the protein level by contacting a microarray of nucleic acid samples derived from a variety of different sources with one or more nucleic acid probes then identifying the sample or samples to which the probe binds is provided.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: September 6, 2011
    Assignee: Life Technologies Corporation
    Inventors: James Hoeffler, Joseph Fernandez, Marc Nasoff
  • Publication number: 20110158999
    Abstract: The present invention provides antibodies or antigen-binding molecules that specifically recognize and antagonize human PAR1 receptor. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors.
    Type: Application
    Filed: January 7, 2011
    Publication date: June 30, 2011
    Applicant: IRM LLC
    Inventors: Steve B. Cohen, Marc Nasoff
  • Patent number: 7888483
    Abstract: The present invention provides antibodies or antigen-binding molecules that specifically recognize and antagonize human PAR1 receptor. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: February 15, 2011
    Assignee: IRM LLC
    Inventors: Steve B Cohen, Marc Nasoff
  • Publication number: 20100150914
    Abstract: TrkB agonist antibodies and methods of their use are provided.
    Type: Application
    Filed: November 6, 2007
    Publication date: June 17, 2010
    Applicant: IRM LLC
    Inventors: Yan Wang, Steven B. Cohen, Marc Nasoff
  • Publication number: 20090286312
    Abstract: Disclosed in the present invention are antibodies that specifically recognize and antagonize human TSLP receptor, and methods of employing these antibodies to treat or ameliorate diseases or disorder mediated by TSLP signaling.
    Type: Application
    Filed: January 11, 2007
    Publication date: November 19, 2009
    Inventors: Liqun Dong, Marc Nasoff
  • Publication number: 20090074747
    Abstract: Disclosed in the present invention are antibodies that specifically recognize and antagonize human TSLP receptor, and methods of employing these antibodies to treat or ameliorate diseases or disorder mediated by TSLP signaling.
    Type: Application
    Filed: June 18, 2008
    Publication date: March 19, 2009
    Inventors: Liqun DONG, Marc Nasoff
  • Publication number: 20080044424
    Abstract: The present invention provides antibodies or antigen-binding molecules that specifically recognize and antagonize human PAR1 receptor. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors.
    Type: Application
    Filed: July 17, 2007
    Publication date: February 21, 2008
    Applicant: IRM LLC
    Inventors: Steve Cohen, Marc Nasoff
  • Patent number: 7229617
    Abstract: Anti-DR4 or Anti-DR5 antibody agonists, combined with apoptosis-inducing agents, synergistically induce apoptosis in cancer cells.
    Type: Grant
    Filed: November 25, 2003
    Date of Patent: June 12, 2007
    Assignee: IRM LLC
    Inventors: Marc Nasoff, Quinn L. Deveraux, Deborah A. Knee, Pedro Aza-Blanc, Garret M. Hampton, Klaus Wagner
  • Publication number: 20070128204
    Abstract: Anti-DR5 antibody agonists, combined with apoptosis-inducing agents, synergistically induce apoptosis in cancer cells.
    Type: Application
    Filed: December 1, 2006
    Publication date: June 7, 2007
    Applicant: IRM LLC
    Inventors: Marc Nasoff, Quinn Deveraux, Deborah Knee, Pedro Aza-Blanc, Garret Hampton, Klaus Wagner
  • Publication number: 20050079172
    Abstract: Anti-DR4 or Anti-DR5 antibody agonists, combined with apoptosis-inducing agents, synergistically induce apoptosis in cancer cells.
    Type: Application
    Filed: November 25, 2003
    Publication date: April 14, 2005
    Applicant: IRM LLC, a Delaware Limited Liability Company
    Inventors: Marc Nasoff, Quinn Deveraux, Deborah Knee, Pedro Aza-Blanc, Garret Hampton, Klaus Wagner
  • Publication number: 20040157322
    Abstract: A fermentation apparatus is constructed to produce a known and repeatable amount of untainted fermentation product using multiple fermentation vessels. To facilitate further processing compatible with other product processing steps, the fermentation apparatus has an array of sample vessels arranged in a container frame. The container frame is configured to hold the sample vessels during fermentation and to transport the vessel array to or from another processing station. Corresponding to the number of sample vessels in the sample vessel array, a cannula array is configured such that each cannula may be placed inside a sample vessel. The cannula array is attached to a gas distributor that delivers oxygen and/or one or more other gases from a gas source through the cannula into the sample vessel. Because the fermentation volume for each individual sample vessel is smaller than a bulk fermentation apparatus, the fermentation product yields are predictable and cell growth rates can be effectively optimized.
    Type: Application
    Filed: February 3, 2004
    Publication date: August 12, 2004
    Applicant: IRM, LLC
    Inventors: Robert Charles Downs, Scott Allan Lesley, James Kevin Mainquist, Daniel Terence McMullan, Andrew J. Meyer, Marc Nasoff